These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22930101)

  • 1. Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study.
    de Boer RA; Azizi M; Danser AJ; Nguyen G; Nussberger J; Ruilope LM; Schmieder RE; Volpe M
    J Renin Angiotensin Aldosterone Syst; 2012 Sep; 13(3):409-12. PubMed ID: 22930101
    [No Abstract]   [Full Text] [Related]  

  • 2. ALTITUDE trial and dual RAS blockade: the alluring but soft science of the surrogate end point.
    Messerli FH; Bangalore S
    Am J Med; 2013 Mar; 126(3):e1-3. PubMed ID: 23332648
    [No Abstract]   [Full Text] [Related]  

  • 3. Which strategy in inhibition of the renin-angiotensin system is the most efficient for heart failure?
    Ogihara T; Rakugi H
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):184-5. PubMed ID: 18957391
    [No Abstract]   [Full Text] [Related]  

  • 4. [Direct renin inhibition: a new and promising treatment principle in heart failure?].
    Mahfoud F; Ukena C; Böhm M
    Dtsch Med Wochenschr; 2009 Apr; 134(15):759-62. PubMed ID: 19340755
    [No Abstract]   [Full Text] [Related]  

  • 5. [Advantages and limitations of renin inhibition with aliskiren].
    Azizi M; Frank M; Steichen O; Blanchard A
    Ann Pharm Fr; 2011 May; 69(3):142-50. PubMed ID: 21570538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges to Data Monitoring Committees When Regulatory Authorities Intervene.
    Swedberg K; Borer JS; Pitt B; Pocock S; Rouleau J
    N Engl J Med; 2016 Apr; 374(16):1580-4. PubMed ID: 27043879
    [No Abstract]   [Full Text] [Related]  

  • 7. Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE.
    Krum H; Massie B; Abraham WT; Dickstein K; Kober L; McMurray JJ;
    Eur J Heart Fail; 2013 Nov; 15(11):1205-7. PubMed ID: 23989432
    [No Abstract]   [Full Text] [Related]  

  • 8. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiotensin therapy: new perspectives.
    Ramasubbu K; Mann DL; Deswal A
    Cardiol Clin; 2007 Nov; 25(4):573-80; vi-vii. PubMed ID: 18063161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aliskiren and dual therapy in type 2 diabetes mellitus.
    Ingelfinger JR
    N Engl J Med; 2008 Jun; 358(23):2503-5. PubMed ID: 18525047
    [No Abstract]   [Full Text] [Related]  

  • 12. Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients.
    López V; Martin M; Cobelo C; Aranda P; Cabello M; Sola E; Gutierrez C; Burgos D; Martínez D; Hernandez D
    Transplant Proc; 2010 Oct; 42(8):2883-5. PubMed ID: 20970559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema.
    Makani H; Bangalore S; Romero J; Wever-Pinzon O; Messerli FH
    Am J Med; 2011 Feb; 124(2):128-35. PubMed ID: 21295192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is there still a place for a dual blockade of the renin-angiotensin system in 2012?].
    Krzesinski JM; Scheen AJ
    Rev Med Suisse; 2012 Aug; 8(351):1598-603. PubMed ID: 22988713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In brief: aliskiren trial terminated.
    Med Lett Drugs Ther; 2012 Jan; 54(1382):5. PubMed ID: 22267213
    [No Abstract]   [Full Text] [Related]  

  • 17. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
    Krum H; Massie B; Abraham WT; Dickstein K; Kober L; McMurray JJ; Desai A; Gimpelewicz C; Kandra A; Reimund B; Rattunde H; Armbrecht J;
    Eur J Heart Fail; 2011 Jan; 13(1):107-14. PubMed ID: 21169387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aliskiren in the treatment of hypertension and organ damage.
    Riccioni G
    Cardiovasc Ther; 2011 Feb; 29(1):77-87. PubMed ID: 21106033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Renin inhibition and the kidney].
    Ecder T
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.